Partnership expands AI capabilities for drug development
Certara, Inc. (NASDAQ:CERT) has announced a collaboration with Nvidia (NASDAQ:NVDA) to integrate the Nvidia BioNeMo Agent Toolkit into its artificial intelligence platform, bringing together Certara’s biosimulation technology, regulatory expertise and proprietary data with advanced agentic AI capabilities.
According to the company, the BioNeMo Agent Toolkit will become one of several AI frameworks available within Certara’s platform, complementing its existing biosimulation software and scientific expertise.
AI agents to support life sciences workflows
The integrated platform is designed to enable AI agents to assist across a broad range of pharmaceutical research and development activities, including dose optimisation, clinical data analysis, patient and trial simulation, ADMET assessment and the preparation of regulatory evidence.
Chief Executive Officer Jon Resnick said: “Agentic AI combined with Certara’s world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need to generate integrated evidence for regulators.”
Collaboration aims to accelerate pharmaceutical innovation
Chief Technology Officer and Chief AI Officer Chris Bouton said the agreement supports the company’s long-term objective of transforming drug development through computational biology.
“Our collaboration with Nvidia and addition of the BioNeMo Agent Toolkit to the integrated platform helps accelerate that vision” of computationally simulating human biology to transform drug discovery and development.
Supporting thousands of life sciences organisations
Certara provides software and scientific services to more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies worldwide.
Headquartered in Radnor, Pennsylvania, the company specialises in model-informed drug development, helping researchers improve efficiency throughout the pharmaceutical development process by combining biosimulation with artificial intelligence.